Sandra M. Swain

51.6k total citations · 11 hit papers
337 papers, 23.4k citations indexed

About

Sandra M. Swain is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Sandra M. Swain has authored 337 papers receiving a total of 23.4k indexed citations (citations by other indexed papers that have themselves been cited), including 246 papers in Oncology, 136 papers in Cancer Research and 89 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Sandra M. Swain's work include HER2/EGFR in Cancer Research (138 papers), Cancer Treatment and Pharmacology (134 papers) and Breast Cancer Treatment Studies (123 papers). Sandra M. Swain is often cited by papers focused on HER2/EGFR in Cancer Research (138 papers), Cancer Treatment and Pharmacology (134 papers) and Breast Cancer Treatment Studies (123 papers). Sandra M. Swain collaborates with scholars based in United States, United Kingdom and Canada. Sandra M. Swain's co-authors include José Baselga, Michael S. Ewer, Fredrick S. Whaley, Javier Cortés, Emma Clark, Graham Ross, Norman Wolmark, Mark Benyunes, Sung‐Bae Kim and James J. Lee and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Sandra M. Swain

328 papers receiving 22.8k citations

Hit Papers

Pertuzumab plus Trastuzumab plus Docetaxel for Metastati... 2003 2026 2010 2018 2011 2003 2015 2009 2013 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
    2011 1.8k citations Javier Cortés, Young‐Hyuck Im et al. New England Journal of Medicine profile →
  2. Congestive heart failure in patients treated with doxorubicin
    2003 1.7k citations Sandra M. Swain et al. Cancer profile →
  3. Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
    2015 1.4k citations Sandra M. Swain, José Baselga et al. New England Journal of Medicine profile →
  4. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
    2009 912 citations Sandra M. Swain et al. profile →
  5. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
    2013 700 citations Sandra M. Swain, Javier Cortés et al. The Lancet Oncology profile →
  6. Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831
    2014 671 citations Edith A. Perez, Edward H. Romond et al. Journal of Clinical Oncology profile →
  7. Targeting HER2-positive breast cancer: advances and future directions
    2022 583 citations Sandra M. Swain, Mythili Shastry et al. Nature Reviews Drug Discovery profile →
  8. Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: NSABP B-31
    2005 568 citations Elizabeth Tan-Chiu, Greg Yothers et al. Journal of Clinical Oncology profile →
  9. Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials
    2017 536 citations Sandra M. Swain et al. Journal of Clinical Oncology profile →
  10. Long-Term Outcomes of Invasive Ipsilateral Breast Tumor Recurrences After Lumpectomy in NSABP B-17 and B-24 Randomized Clinical Trials for DCIS
    2011 517 citations Richard G. Margolese, Sandra M. Swain et al. JNCI Journal of the National Cancer Institute profile →
  11. HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now
    2021 176 citations Ilana Schlam, Sandra M. Swain profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sandra M. Swain United States 66 15.4k 7.2k 5.1k 4.9k 4.8k 337 23.4k
Luca Gianni Italy 72 20.5k 1.3× 8.3k 1.2× 8.2k 1.6× 5.7k 1.2× 6.0k 1.2× 309 30.7k
Steven Shak United States 54 16.7k 1.1× 11.2k 1.6× 8.1k 1.6× 6.0k 1.2× 5.6k 1.2× 133 28.1k
Karen A. Gelmon Canada 73 15.9k 1.0× 7.0k 1.0× 5.6k 1.1× 2.3k 0.5× 6.6k 1.4× 393 23.8k
Brian Leyland‐Jones United States 53 11.6k 0.8× 4.6k 0.6× 5.7k 1.1× 4.1k 0.8× 3.3k 0.7× 218 18.4k
Edith A. Perez United States 79 20.7k 1.3× 11.1k 1.5× 6.6k 1.3× 4.4k 0.9× 5.8k 1.2× 400 30.1k
Vicente Valero United States 94 17.3k 1.1× 13.2k 1.8× 5.4k 1.1× 2.9k 0.6× 4.9k 1.0× 500 27.9k
Evandro de Azambuja Belgium 58 10.7k 0.7× 4.7k 0.6× 3.1k 0.6× 2.5k 0.5× 3.6k 0.7× 351 15.4k
George W. Sledge United States 72 14.8k 1.0× 9.6k 1.3× 7.5k 1.5× 2.5k 0.5× 6.3k 1.3× 444 25.4k
Louis Fehrenbacher United States 63 25.3k 1.6× 8.0k 1.1× 8.9k 1.7× 4.5k 0.9× 10.2k 2.1× 157 35.9k
William Novotny United States 38 12.5k 0.8× 3.8k 0.5× 8.0k 1.6× 2.6k 0.5× 5.7k 1.2× 110 22.6k

Countries citing papers authored by Sandra M. Swain

Since Specialization
Citations

This map shows the geographic impact of Sandra M. Swain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandra M. Swain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandra M. Swain more than expected).

Fields of papers citing papers by Sandra M. Swain

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandra M. Swain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandra M. Swain. The network helps show where Sandra M. Swain may publish in the future.

Co-authorship network of co-authors of Sandra M. Swain

This figure shows the co-authorship network connecting the top 25 collaborators of Sandra M. Swain. A scholar is included among the top collaborators of Sandra M. Swain based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandra M. Swain. Sandra M. Swain is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Schlam, Ilana, Sherene Loi, Roberto Salgado, & Sandra M. Swain. (2025). Tumor-infiltrating lymphocytes in HER2-positive breast cancer: potential impact and challenges. ESMO Open. 10(2). 104120–104120. 7 indexed citations
2.
Lambertini, Matteo, Deirdre Allegranza, Ruediger P. Laubender, et al.. (2025). Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients. JNCI Journal of the National Cancer Institute. 117(11). 2317–2326.
3.
Rastogi, Priya, Hanna Bandos, Peter C. Lucas, et al.. (2024). Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial. Journal of Clinical Oncology. 42(30). 3561–3569. 3 indexed citations
4.
Rastogi, Priya, Gong Tang, Saima Hassan, et al.. (2023). Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41. Breast Cancer Research and Treatment. 199(2). 243–252. 4 indexed citations
5.
6.
Swain, Sandra M., Mythili Shastry, & Erika Hamilton. (2022). Targeting HER2-positive breast cancer: advances and future directions. Nature Reviews Drug Discovery. 22(2). 101–126. 583 indexed citations breakdown →
7.
Khoury, Katia, Filipa Lynce, Ana Barac, et al.. (2021). Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function. Breast Cancer Research and Treatment. 185(3). 863–868. 20 indexed citations
8.
Cobleigh, Melody, Denise A. Yardley, Adam Brufsky, et al.. (2019). Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs. Clinical Cancer Research. 26(5). 1105–1113. 23 indexed citations
9.
Tripathy, Debu, Adam Brufsky, Melody Cobleigh, et al.. (2019). De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry. The Oncologist. 25(2). e214–e222. 45 indexed citations
10.
Perez, Edith A., Edward H. Romond, Vera J. Suman, et al.. (2014). Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831. Journal of Clinical Oncology. 32(33). 3744–3752. 671 indexed citations breakdown →
11.
12.
Kaufman, Peter A., Kenneth J. Bloom, Howard A. Burris, et al.. (2014). Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2‐negative breast cancer. Cancer. 120(17). 2657–2664. 47 indexed citations
13.
Robidoux, André, Gong Tang, Priya Rastogi, et al.. (2013). Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. The Lancet Oncology. 14(12). 1183–1192. 261 indexed citations
14.
Cortés, Javier, Sandra M. Swain, Iveta Kudaba, et al.. (2013). Absence of pharmacokinetic drug–drug interaction of pertuzumab with trastuzumab and docetaxel. Anti-Cancer Drugs. 24(10). 1084–1092. 19 indexed citations
15.
16.
17.
Bear, Harry D., Gong Tang, Priya Rastogi, et al.. (2012). Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer. New England Journal of Medicine. 366(4). 310–320. 320 indexed citations
18.
Yang, Sherry, Richard Simon, Antoinette R. Tan, Diana Nguyen, & Sandra M. Swain. (2005). Gene Expression Patterns and Profile Changes Pre- and Post-Erlotinib Treatment in Patients with Metastatic Breast Cancer. Clinical Cancer Research. 11(17). 6226–6232. 26 indexed citations
19.
Tan-Chiu, Elizabeth, Greg Yothers, Edward H. Romond, et al.. (2005). Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: NSABP B-31. Journal of Clinical Oncology. 23(31). 7811–7819. 568 indexed citations breakdown →
20.
McCarthy, Nicole & Sandra M. Swain. (2001). Tumor markers: should we or shouldn't we?. PubMed. 7(3). 175–7. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Luca Gianni Breakdown of academic impact, for papers by Steven Shak Breakdown of academic impact, for papers by Karen A. Gelmon Breakdown of academic impact, for papers by Brian Leyland‐Jones Breakdown of academic impact, for papers by Edith A. Perez Breakdown of academic impact, for papers by Vicente Valero Breakdown of academic impact, for papers by Evandro de Azambuja Breakdown of academic impact, for papers by George W. Sledge Breakdown of academic impact, for papers by Louis Fehrenbacher Breakdown of academic impact, for papers by William Novotny
Rankless by CCL
2026